skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

99+ Total results for product and free and sample content found

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

A Visual Guide To US FDA's Evolutionary Decade In Review

16 Jan 2020

An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.

Topic fda policy-and-regulation

Medtech Insight: 世界の医療機器・医療技術の最新情報

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 1)

15 Jan 2020

Compliance_Corner_Part_1

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.

Medtech Insight: 世界の医療機器・医療技術の最新情報

Exec Chat: CES 2020: For FDA's Amy Abernethy It's About Data, But Also Community Engagement

15 Jan 2020

Amy Abernethy, FDA's principal deputy commissioner, sat down with Medtech Insight during CES 2020 to discuss the agency's progress on the Technology Modernization Action Plan, the pre-certification program for digital health products, and the FDA's plans for 2020.

Topic Digital Health FDA

Medtech Insight: 世界の医療機器・医療技術の最新情報

FDA Will Keep Listening To Patient-Engagement Experts

By ferdous-al-faruque 08 Jan 2020

FDA_Will_Keep_Listening

The US agency says in a 6 January Federal Register notice that it’s keeping its Patient Engagement Advisory Committee in place through October 2021 so it can gather more patient feedback that will come in handy when regulatory decisions need to be made. The committee, formed after the agency made a cultural shift to consider patient input on the types of products it allows on the market, was supposed to expire October 2019.

HBW Insight : コンシューマーヘルスケア産業のニュース

'Supplement' on CBD Product Label A Bullseye For US Litigants, Says Attorney

18 Dec 2019

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Medtech Insight: 世界の医療機器・医療技術の最新情報

FDA Proposes End To Quarterly Reporting On HDE, PMA Decisions

By elizabeth-orr 18 Dec 2019

A proposal from the US FDA would end quarterly publication of PMA and Humanitarian Device Exemption verdicts in the Federal Register. The agency says the practice is inefficient and duplicates online publication.

HBW Insight : コンシューマーヘルスケア産業のニュース

US Senate Passes First Monograph Reform Bill After House Passed Three

11 Dec 2019

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

HBW Insight : コンシューマーヘルスケア産業のニュース

Future of CBD In Supplements: NDI Notification Looms As Regulatory Path

06 Dec 2019

Article

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Former FDA Commissioner Frank Young Passes Away At 88

By Michael Cipriano 28 Nov 2019

From the approval of AZT to the generic drug scandal, Frank Young oversaw many seminal events at US FDA while commissioner from 1984 to 1989. After leaving the agency, he managed the approval of the NDA for Braeburn's opioid dependence drug Probuphine. Young passed away following a short bout with cancer.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。